News

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

On Tuesday, Biomea Fusion Inc. (NASDAQ:BMEA) revealed topline results from the ongoing COVALENT-111 study of icovamenib in patients with type 2 diabetes (T2D). Icovamenib was investigated in three different dosing arms with a primary follow-up after 26 weeks: Arm A at 100mg QD (once daily) for 8 weeks, Arm B at 100mg QD for 12 weeks, and Arm C at 100 mg QD for 8 weeks and 100mg BID (twice daily) for 4 weeks. Also Read: FDA Removes Clinical Hold On Biomea Fusion’s Early-Stage Trials For Potential

Bitcoin Rally Leaves the World’s Original Crypto ETFs Behind

(Bloomberg) -- In what’s been a record-breaking year for Bitcoin, the originators of the world’s first exchange-traded funds to hold the cryptocurrency appear to be at risk of being left behind. Most Read from BloombergHow California Sees the World, and ItselfHong Kong's Expat Party Hub Reshaped by Chinese InfluxLondon’s Tube Fares Are Set to Rise by 4.6% Next YearBitcoin ETFs were launched in Canada in February 2021, making them the first in the world. This led to billions of dollars of inflows